



# Washington University in St. Louis Forum for Greater China

Island Shangri-La | Hong Kong  
December 14, 2018

## Personalized Medicine and the Future of Health Care



**Leming SHI, PhD**  
**Professor**  
**Fudan University**

Dr. Shi received his Ph.D. in computational chemistry and chemometrics from the Chinese Academy of Sciences in Beijing, M.Sc. in chemometrics from the University of Science and Technology of China in Hefei, and B.Sc. in analytical chemistry from Hunan University in Changsha, China. Dr. Shi conducted postdoctoral training at Case Western Reserve University and the NIH/NCI. Dr. Shi was a senior research scientist at Wyeth (now Pfizer) and BASF before co-founding Chipscreen in 2001. Dr. Shi is a guest faculty at the US FDA and an adjunct professor of medicine at the University of Arkansas for Medical Sciences.

Dr. Leming Shi is a distinguished professor at the School of Life Sciences of Fudan University in Shanghai, China where he established and directs the Center for Pharmacogenomics and Fudan-Zhangjiang Center for Clinical Genomics.

As a principal investigator at the US Food and Drug Administration (FDA) from 2003 to 2012, Dr. Shi conceived and led the MicroArray and Sequencing Quality Control (MAQC/SEQC) project aimed at realizing precision medicine by standardizing genomics and bioinformatics ([www.nature.com/nbt/focus/maqc/](http://www.nature.com/nbt/focus/maqc/), [www.nature.com/focus/maqc2/](http://www.nature.com/focus/maqc2/), and [www.nature.com/nbt/collections/seqc/](http://www.nature.com/nbt/collections/seqc/)).

Dr. Shi was a co-founder of Chipscreen Biosciences Ltd. in Shenzhen, China where he co-developed a chemogenomics-based drug discovery platform leading to several novel small-molecule drug candidates with promising efficacy and safety profiles in anticancer and antidiabetic clinical trials, with one novel compound approved in 2014 by China FDA for treating T-cell lymphoma.